In partnership with ESWI, the Coalition for Life Course Immunisation has released a new policy brief highlighting the urgent need for a more coordinated, life-course approach to respiratory virus prevention across the EU.

Check out this Satellite Symposium organised by the ESWI IDC and supported by IFPMA and Sanofi from ESWI2026.

Passive immunisation with long-acting monoclonal antibodies (nirsevimab) targeting the two antigenic subgroups A and B of respiratory syncytial virus (RSV) was authorised by the European Medicines Agency for use in the European Union on 31 October 2022.

The safety and efficacy profiles of available RSV vaccines, a critical consideration for their integration into public health strategies and clinical practice, remain uncertain.

As COVID-19 transitions from a pandemic to an endemic disease, its integration into the broader policy and healthcare framework for respiratory diseases becomes imperative.

This year, 15 October marks the evolution of #EUFluDay into #EURespiDay, a broader call for EU action on respiratory infection prevention.

With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute CardioVascular Care (ACVC), and the Heart Failure Association (HFA) of the ESC

Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein.